Pharma Foods International Co., Ltd. (TYO:2929)
Japan · Delayed Price · Currency is JPY 691.00
-1.00 (-0.14%)
Sep 14, 2026, 3:30 PM JST
TYO:2929 Income Statement
Financials in millions JPY. Fiscal year is August - July.
Millions JPY. Fiscal year is Aug - Jul.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
| 63,223 | 65,260 | 62,147 | 68,572 | 60,185 | |
Revenue Growth | -3.12% | 5.01% | -9.37% | 13.94% | 28.73% |
Cost of Revenue | 12,530 | 12,676 | 13,395 | 13,293 | 12,077 |
Gross Profit | 50,693 | 52,584 | 48,752 | 55,279 | 48,108 |
Selling, General & Admin | 46,168 | 48,763 | 42,561 | 50,757 | 46,211 |
Research & Development | 1,858 | 1,399 | 978 | 840 | 766 |
Amortization of Goodwill & Intangibles | 34 | 53 | 99 | 72 | 51 |
Operating Expenses | 48,060 | 50,215 | 43,638 | 51,669 | 47,028 |
Operating Income | 2,633 | 2,369 | 5,114 | 3,610 | 1,080 |
Interest Expense | -161 | -91 | -62 | -48 | -26 |
Interest & Investment Income | 56 | 39 | 29 | 27 | 38 |
Earnings From Equity Investments | -203 | -131 | -35 | -82 | 5 |
Currency Exchange Gain (Loss) | 1 | -1 | 4 | 8 | 37 |
Other Non Operating Income (Expenses) | 114 | 367 | 198 | 76 | 130 |
EBT Excluding Unusual Items | 2,440 | 2,552 | 5,248 | 3,591 | 1,264 |
Gain (Loss) on Sale of Investments | -117 | -118 | -113 | -50 | 81 |
Gain (Loss) on Sale of Assets | 4 | - | - | -6 | 77 |
Asset Writedown | - | - | -101 | - | - |
Other Unusual Items | - | - | -1 | 8 | 1 |
Pretax Income | 2,327 | 2,434 | 5,033 | 3,543 | 1,423 |
Income Tax Expense | 339 | 2,066 | 1,828 | 462 | 1,797 |
Earnings From Continuing Operations | 1,988 | 368 | 3,205 | 3,081 | -374 |
Net Income | 1,988 | 368 | 3,205 | 3,081 | -374 |
Net Income to Common | 1,988 | 368 | 3,205 | 3,081 | -374 |
Net Income Growth | 440.22% | -88.52% | 4.03% | - | - |
Shares Outstanding (Basic) | 29 | 29 | 28 | 29 | 29 |
Shares Outstanding (Diluted) | 29 | 29 | 28 | 29 | 29 |
Shares Change | 0.82% | 1.06% | -1.51% | -0.47% | -0.18% |
EPS (Basic) | 68.60 | 12.80 | 112.69 | 106.70 | -12.89 |
EPS (Diluted) | 68.60 | 12.80 | 112.69 | 106.70 | -12.89 |
EPS Growth | 435.82% | -88.64% | 5.62% | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
Free Cash Flow | - | -1,983 | 4,645 | 5,739 | -6,532 |
Free Cash Flow Per Share | - | -68.99 | 163.32 | 198.74 | -225.13 |
Dividend Per Share | - | 25.000 | 25.000 | 22.000 | 20.000 |
Dividend Growth | - | 0% | 13.64% | 10.00% | 0% |
Gross Margin | 80.18% | 80.58% | 78.45% | 80.62% | 79.93% |
Operating Margin | 4.17% | 3.63% | 8.23% | 5.27% | 1.79% |
Profit Margin | 3.14% | 0.56% | 5.16% | 4.49% | -0.62% |
Free Cash Flow Margin | - | -3.04% | 7.47% | 8.37% | -10.85% |
EBITDA | 3,346 | 3,154 | 6,021 | 4,156 | 1,600 |
EBITDA Margin | 5.29% | 4.83% | 9.69% | 6.06% | 2.66% |
D&A For EBITDA | 713.33 | 785 | 907 | 546 | 520 |
EBIT | 2,633 | 2,369 | 5,114 | 3,610 | 1,080 |
EBIT Margin | 4.17% | 3.63% | 8.23% | 5.27% | 1.79% |
Effective Tax Rate | 14.57% | 84.88% | 36.32% | 13.04% | 126.28% |
Advertising Expenses | 33,917 | 36,692 | 30,787 | 38,865 | 35,748 |